<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118297</url>
  </required_header>
  <id_info>
    <org_study_id>201612002</org_study_id>
    <nct_id>NCT03118297</nct_id>
  </id_info>
  <brief_title>Intervention to End Recurrent Unscheduled Bleeding Trial</brief_title>
  <acronym>INTERRUPT</acronym>
  <official_title>Intervention to End Recurrent Unscheduled Bleeding Trial: A Randomized-controlled Trial of Ulipristal Acetate for Unscheduled Bleeding in Etonogestrel Implant Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The subdermal etonogestrel (ENG) implant, a long-acting reversible contraceptive (LARC)
      method, is among the most effective forms of reversible contraception and thus, an important
      tool in the quest to reduce unintended pregnancy. However, despite overall increases in LARC
      use in the United States from 1.5% in 2002 to 7.2% in 2011, and 11.6% most recently in 2015,
      implant use continues to make up a small proportion of LARC use. While evidence to explain
      this low uptake of implants is lacking, one potential reason is patient and provider concerns
      about unpredictable bleeding.

      As a result of this, many studies have been performed in attempts to discover therapies for
      unscheduled bleeding in progestin-only contraceptive users. Some of these studies include
      those investigating selective progesterone receptor modulators, such as mifepristone and
      ulipristal acetate (UPA), which did find some benefit. Although a previous study showed mixed
      benefit, the investigators feel that this medication has demonstrated both biologic
      plausibility as well as clinically important outcomes. This previous study may not be
      entirely translatable to the proposed research as therapies were used for different
      indications (prophylaxis vs. treatment) and different progestins and delivery systems were
      studied. Therefore, the investigators believe UPA should not be discounted as a potential
      therapy. UPA may provide an additional safe and effective option for treatment of irregular
      bleeding with implants in women. In addition, UPA is currently available in outpatient
      pharmacies in the U.S. as a single 30mg oral tablet.

      The investigators propose to investigate UPA for the treatment of unscheduled and troublesome
      bleeding in ENG implant users.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subdermal etonogestrel (ENG) implant, a long-acting reversible contraceptive (LARC)
      method, is among the most effective forms of reversible contraception and thus, an important
      tool in the quest to reduce unintended pregnancy. Despite this, ENG implant users make up a
      small percent of overall women that use LARC in the United States. Previous studies have
      demonstrated that among women dissatisfied with their implant, the majority cite
      unpredictable and irregular bleeding as a primary reason. Dissatisfaction with a
      contraceptive method can lead to discontinuation, which can put a woman at risk for unplanned
      pregnancy. Although irregular bleeding is a common side effect of all progestin-only
      contraceptives, there are significant gaps in our knowledge regarding the etiology of and
      effective therapies for unscheduled bleeding. While several mechanisms have been proposed and
      therapies have been studied, lack of convincing scientific evidence, in addition to possible
      contraindications to these therapies, demonstrates the need to investigate additional
      effective interventions.

      Studies evaluating interventions for abnormal uterine bleeding resulting from uterine
      leiomyoma provide insight into potential therapies for progestin-mediated bleeding. In prior
      studies, ulipristal acetate (UPA) has been shown to reduce bleeding symptoms associated with
      uterine leiomyoma, including decreasing or stopping excessive bleeding. Progestin-associated
      irregular bleeding has been proposed to be secondary to a disruption in endometrial
      angiogenesis, therefore creating a fragile venous network. UPA may displace local progestin
      to counteract this effect. Thus, this medication has demonstrated both biologic plausibility
      as well as clinically important benefits. UPA may provide an additional safe and effective
      option for treatment of irregular bleeding in implant users. As women are often dissatisfied
      with irregular bleeding with the implant as noted above, improving bleeding profiles could
      potentially improve uptake and continuation of the device.

      The investigators will perform a double blinded, randomized, placebo-controlled trial. Women
      will be randomized to receive either 15mg of UPA daily for 7 days or placebo for the same
      duration. The investigators hypothesize that UPA will decrease bleeding and spotting days in
      users of the ENG implant with unscheduled bleeding when compared to placebo as assessed by
      daily bleeding diaries.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">January 31, 2018</completion_date>
  <primary_completion_date type="Actual">January 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Bleeding/Spotting Days With Use of Ulipristal Acetate as Measured by Daily Bleeding Diaries</measure>
    <time_frame>30 days</time_frame>
    <description>To evaluate the effectiveness of ulipristal acetate (15mg) in decreasing bleeding/spotting days due to the ENG implant over a 30-day period as compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Cessation by Day 10</measure>
    <time_frame>10 days</time_frame>
    <description>To evaluate bleeding cessation rates by day 10 following seven days of treatment with either ulipristal acetate or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Satisfaction With Bleeding Pattern at 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>To evaluate participant satisfaction with regards to bleeding pattern after use of ulipristal acetate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Medication Side Effects by 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>To evaluate participant satisfaction with regards to medication side effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovulation Status Measured by Weekly Serum Progesterone Levels</measure>
    <time_frame>Baseline, weeks 1, 2, 3, 4</time_frame>
    <description>To evaluate effect, if any, of ulipristal acetate on ovulation status. Data in the table represent the lowest and highest values that were recorded over all of the measurements for each arm as a whole.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Contraception</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Ulipristal Acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg ulipristal acetate (capsule) daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical placebo (capsule) daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulipristal Acetate</intervention_name>
    <description>Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
    <arm_group_label>Ulipristal Acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women age 18-45

          -  Implant placed &gt;90 days and &lt;3 years prior to enrollment

          -  Patient complaint of bothersome irregular bleeding with implant

          -  Willing to be abstinent or use condoms during study period

          -  Willing to complete 30-day bleeding diary

          -  Willing to be randomized to placebo or ulipristal acetate

          -  Ability to send/receive SMS text message

        Exclusion Criteria:

          -  Non-English speaking

          -  Implant placed &gt;3 years prior to enrollment

          -  Contraindication to ulipristal acetate (current use of barbiturates, bosentan,
             carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's
             Wort, topiramate, known or suspected pregnancy, hypersensitivity to active substance
             or excipients, uterine/cervical/ovarian/breast cancer, severe asthma insufficiently
             controlled by oral glucocorticoids)

          -  Inability or unwillingness to comply with medication protocol

          -  Inability or unwillingness to comply with bleeding diary

          -  Breastfeeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Zigler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <results_first_submitted>June 27, 2018</results_first_submitted>
  <results_first_submitted_qc>August 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2018</results_first_posted>
  <last_update_submitted>August 28, 2018</last_update_submitted>
  <last_update_submitted_qc>August 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Rachel Zigler, MD MSCI</investigator_full_name>
    <investigator_title>Clinical Fellow</investigator_title>
  </responsible_party>
  <keyword>Etonogestrel Implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulipristal acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT03118297/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ulipristal Acetate</title>
          <description>15mg ulipristal acetate (capsule) daily for 7 days
Ulipristal Acetate: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Identical appearing placebo (capsule) daily for 7 days
Placebo oral capsule: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ulipristal Acetate</title>
          <description>15mg ulipristal acetate (capsule) daily for 7 days
Ulipristal Acetate: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Identical placebo (capsule) daily for 7 days
Placebo oral capsule: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>2 participants lost to follow up in placebo group</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.4" spread="6.2"/>
                    <measurement group_id="B2" value="25.5" spread="6.3"/>
                    <measurement group_id="B3" value="26.0" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>2 participants lost to follow up in placebo group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>2 participants lost to follow up in placebo group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>2 participants lost to follow up in placebo group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other or multiracial</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>2 participants lost to follow up in placebo group</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <population>2 participants lost to follow up in placebo group</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.6" spread="8.2"/>
                    <measurement group_id="B2" value="27.8" spread="7.0"/>
                    <measurement group_id="B3" value="28.7" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of implant use</title>
          <population>2 participants lost to follow up in placebo group</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.9" lower_limit="5.5" upper_limit="18.1"/>
                    <measurement group_id="B2" value="9.2" lower_limit="5.9" upper_limit="19.3"/>
                    <measurement group_id="B3" value="10.1" lower_limit="5.7" upper_limit="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Days of bleeding in 30 days prior to enrollment</title>
          <population>2 participants lost to follow up in placebo group</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.5" lower_limit="12.5" upper_limit="29.5"/>
                    <measurement group_id="B2" value="20.0" lower_limit="14.0" upper_limit="28.0"/>
                    <measurement group_id="B3" value="20.3" lower_limit="13.3" upper_limit="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Bleeding/Spotting Days With Use of Ulipristal Acetate as Measured by Daily Bleeding Diaries</title>
        <description>To evaluate the effectiveness of ulipristal acetate (15mg) in decreasing bleeding/spotting days due to the ENG implant over a 30-day period as compared to placebo.</description>
        <time_frame>30 days</time_frame>
        <population>See baseline characteristics</population>
        <group_list>
          <group group_id="O1">
            <title>Ulipristal Acetate</title>
            <description>15mg ulipristal acetate (capsule) daily for 7 days
Ulipristal Acetate: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo (capsule) daily for 7 days
Placebo oral capsule: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Bleeding/Spotting Days With Use of Ulipristal Acetate as Measured by Daily Bleeding Diaries</title>
          <description>To evaluate the effectiveness of ulipristal acetate (15mg) in decreasing bleeding/spotting days due to the ENG implant over a 30-day period as compared to placebo.</description>
          <population>See baseline characteristics</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="4.5" upper_limit="11.0"/>
                    <measurement group_id="O2" value="12" lower_limit="6.0" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Threshold for significance: p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Cessation by Day 10</title>
        <description>To evaluate bleeding cessation rates by day 10 following seven days of treatment with either ulipristal acetate or placebo.</description>
        <time_frame>10 days</time_frame>
        <population>See baseline characteristics</population>
        <group_list>
          <group group_id="O1">
            <title>Ulipristal Acetate</title>
            <description>15mg ulipristal acetate (capsule) daily for 7 days
Ulipristal Acetate: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo (capsule) daily for 7 days
Placebo oral capsule: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Cessation by Day 10</title>
          <description>To evaluate bleeding cessation rates by day 10 following seven days of treatment with either ulipristal acetate or placebo.</description>
          <population>See baseline characteristics</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.032</p_value>
            <p_value_desc>Threshold for significance: p=0.05</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Satisfaction With Bleeding Pattern at 30 Days</title>
        <description>To evaluate participant satisfaction with regards to bleeding pattern after use of ulipristal acetate.</description>
        <time_frame>30 days</time_frame>
        <population>See baseline characteristics</population>
        <group_list>
          <group group_id="O1">
            <title>Ulipristal Acetate</title>
            <description>15mg ulipristal acetate (capsule) daily for 7 days
Ulipristal Acetate: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo (capsule) daily for 7 days
Placebo oral capsule: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Satisfaction With Bleeding Pattern at 30 Days</title>
          <description>To evaluate participant satisfaction with regards to bleeding pattern after use of ulipristal acetate.</description>
          <population>See baseline characteristics</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Not at all happy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Somewhat unhappy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neither happy nor unhappy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Somewhat happy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very happy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Did not respond</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Threshold for significance: p=0.05</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Medication Side Effects by 30 Days</title>
        <description>To evaluate participant satisfaction with regards to medication side effects.</description>
        <time_frame>30 days</time_frame>
        <population>See baseline characteristics</population>
        <group_list>
          <group group_id="O1">
            <title>Ulipristal Acetate</title>
            <description>15mg ulipristal acetate (capsule) daily for 7 days
Ulipristal Acetate: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo (capsule) daily for 7 days
Placebo oral capsule: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Medication Side Effects by 30 Days</title>
          <description>To evaluate participant satisfaction with regards to medication side effects.</description>
          <population>See baseline characteristics</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling flushed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not experience</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Threshold for significance: p=0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ovulation Status Measured by Weekly Serum Progesterone Levels</title>
        <description>To evaluate effect, if any, of ulipristal acetate on ovulation status. Data in the table represent the lowest and highest values that were recorded over all of the measurements for each arm as a whole.</description>
        <time_frame>Baseline, weeks 1, 2, 3, 4</time_frame>
        <population>See baseline characteristics</population>
        <group_list>
          <group group_id="O1">
            <title>Ulipristal Acetate</title>
            <description>15mg ulipristal acetate (capsule) daily for 7 days
Ulipristal Acetate: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo (capsule) daily for 7 days
Placebo oral capsule: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ovulation Status Measured by Weekly Serum Progesterone Levels</title>
          <description>To evaluate effect, if any, of ulipristal acetate on ovulation status. Data in the table represent the lowest and highest values that were recorded over all of the measurements for each arm as a whole.</description>
          <population>See baseline characteristics</population>
          <units>ng/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lower endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No statistical test performed</non_inferiority_desc>
            <other_analysis_desc>Significance testing not performed. All values below prespecified limit of 5.0 ng/mL.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ulipristal Acetate</title>
          <description>15mg ulipristal acetate (capsule) daily for 7 days
Ulipristal Acetate: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Identical placebo (capsule) daily for 7 days
Placebo oral capsule: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Intervention To End Recurrent Unscheduled bleeding Trial (INTERRUPT): A randomized-controlled trial</name_or_title>
      <organization>WashingtonU</organization>
      <phone>3143228697</phone>
      <email>rachelezig@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

